Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the phenylpyrroline class. It has been studied as an inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for cell division. KSP inhibitors are being explored as potential anticancer agents due to their ability to disrupt mitosis in rapidly dividing tumor cells. The compound was developed during efforts to optimize KSP inhibition while minimizing off-target effects such as hERG channel binding and P-glycoprotein-mediated efflux. While related analogs have advanced into clinical trials (e.g., MK‐0731), this specific molecule is primarily referenced in medicinal chemistry literature and chemical databases as an experimental or tool compound[6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (2S)-4-(2,5-difluorophenyl)-N-methyl-2-phenyl-N-piperidin-4-yl-2,5-dihydro-1H-pyrrole-1-carboxamide.